agdaddy04 said:

---

Obviously I've got a pretty big interest in NVDA. Can we really trust what China is saying about deepseek?

https://news.ycombinator.com/item?id=42824033

---

I wouldn't underestimate China's ability to spy, steal, copy, and lie. They are the GOAT. The good news is that we no longer have a POTUS totally compromised by China, and can now hit back.

Also DeepSeek is really good.....did this in under a minute....... (sorry for the long post)

My original question to DeepSeek: based on historical data, trends, and guidance, which 10 stocks in the united states do you expect to see the biggest percentile gains in 2025?

DeepSeek's Response:
Found 50 results
Thought for 18 seconds

Okay, let's tackle this question. The user wants to know which 10 U.S. stocks are expected to have the biggest percentile gains in 2025 based on historical data, trends, and guidance. I need to go through the provided search results and pick out the most relevant information.

First, looking at the Forbes article (webpage 1), it mentions sectors like manufacturing, small- and mid-caps, defense tech, and AI. Experts there are talking about companies like Cellebrite DI and Heico. Then Kiplinger's list (webpage 2) has specific picks like CLBT, HEI, MGM, ZETA, EWM, ADBE, WHR, SHOP, UNH, CEG. The Motley Fool (webpage 3) includes Nvidia, Amazon, Viking Therapeutics, etc. Ameriprise (webpage 4) talks about tech, cyclicals, and diversification. Webpage 5 seems to have an error, so I'll skip that. Markets.com (webpage 6) lists big tech names like Apple, Amazon, Alphabet. Yahoo Finance (webpage 7) is bullish on Amazon. Webpage 8 in Chinese mentions Block (Square) and M&T Bank. Seeking Alpha (webpage 9) has a list including Alphabet, Amazon, Nvidia, etc. Finally, Mark Lyttleton's predictions (webpage 10) focus on tech, healthcare, energy, with mentions of Nvidia and AI.

I need to cross-reference these sources. The challenge is to identify stocks mentioned across multiple sources or highlighted for high growth potential. For example, Nvidia appears in webpage 3, 7, 9, and 10. Amazon is in 3, 6, 7, 9. Cellebrite DI (CLBT) from Kiplinger and others. Then there's Shopify (SHOP) in Kiplinger. Also, looking at sectors like AI, defense tech, fintech, and energy.

Need to check which stocks are expected to have high growth based on the reasons provided. For instance, Viking Therapeutics is in phase 3 trials for obesity drugs, which could be a big catalyst. Heico benefits from aerospace and defense spending. Constellation Energy (CEG) from Kiplinger is in energy, driven by AI data centers and EVs. Zeta Global uses AI for consumer data.

Also, the financial sector picks from webpage 8: Block (Square) and M&T Bank. However, since the user is looking for percentile gains, maybe smaller caps or growth stocks would have higher potential. For example, Cellebrite is a small cap with high growth mentioned. Shopify, despite being a large company, has dropped in price and might rebound.

I should compile a list combining these insights, ensuring each pick has a solid rationale from the sources. Avoid duplicates and prioritize those with the strongest growth catalysts. Let's see:

1. Nvidia (NVDA) - AI chips, Blackwell architecture, high demand.
2. Amazon (AMZN) - Cloud and AI growth, margin expansion.
3. Cellebrite DI (CLBT) - Digital forensics, AI tools, small cap.
4. Viking Therapeutics (VKTX) - Obesity drug phase 3, high upside.
5. Heico (HEI) - Aerospace parts, defense spending.
6. Zeta Global (ZETA) - AI-driven consumer analytics.
7. Shopify (SHOP) - E-commerce platform, recovery potential.
8. Constellation Energy (CEG) - Electricity demand from AI and EVs.
9. Block (SQ/XYZ) - Fintech innovation, Cash App growth.
10. Palantir (PLTR) - AI software, commercial and government growth.

Check if these are all from the sources. Yes, NVDA in 3,7,9,10. AMZN in 3,6,7,9. CLBT in 2. VKTX in 3. HEI in 2. ZETA in 2. SHOP in 2. CEG in 2. Block in 8. Palantir in 3. Also, the user might want to include some from webpage 10 like healthcare, but Viking covers that. Need to ensure each has a strong citation. Also, verify that the percentile gains are supported, like high growth sectors. Okay, this seems to cover the most mentioned and high-potential stocks across the sources.

The End Report:
Based on an analysis of market trends, expert forecasts, and sector-specific growth catalysts from the provided sources, here are 10 U.S. stocks poised for significant gains in 2025, along with key drivers and citations:

1. Nvidia (NVDA)

• Catalysts: Dominance in AI chips (Blackwell architecture), surging demand for data center GPUs, and projected revenue growth from AI infrastructure spending. Analysts highlight its "staggering" demand and innovation leadership 71113.
• Valuation: Forward P/E of 43x, considered reasonable for its growth trajectory 7.

2. Amazon (AMZN)

• Catalysts: Margin expansion in AWS (35% operating margin) and e-commerce, AI-driven efficiency gains, and rising cloud adoption. Predicted to become the world's largest company by market cap in 2025 1113.
• Growth: AWS revenue hit a $110 billion annualized run rate, with AI spending boosting cloud demand 711.

3. Cellebrite DI (CLBT)

• Catalysts: AI-powered digital forensics tools for law enforcement; 25% YoY revenue growth. High-risk, high-reward small-cap pick with upside potential 4.
• Valuation: Forward P/E of 49, but recent 171% 1-year return signals momentum 4.

4. Viking Therapeutics (VKTX)

• Catalysts: Phase 3 trials for obesity drug VK2735 (competing with Eli Lilly's Zepbound). Positive trial data could trigger explosive growth 7.
• Risk/Reward: Clinical-stage biotech with no revenue yet but 120% single-day gains post-trial updates 7.

5. Heico (HEI)

• Catalysts: Aerospace parts supplier benefiting from defense spending and travel recovery. Earnings projected to grow 17% annually through 2030 48.
• Performance: Doubled in 4 years; undervalued relative to growth 4.

6. Zeta Global (ZETA)

• Catalysts: AI-driven consumer analytics platform; LiveIntent acquisition expands e-commerce monetization. Stock tripled in 5 years, with further growth potential 4.
• Growth: 254% 1-year return, positioned in high-demand AI marketing tools 4.

7. Shopify (SHOP)

• Catalysts: E-commerce platform recovery post-2021 slump; 20% annual revenue growth. Trading at a discount with renewed focus on profitability 413.
• Valuation: Forward P/E of 42, down 50% from 2021 highs 4.

8. Constellation Energy (CEG)

• Catalysts: Electricity demand surge from AI data centers and EVs. Stock doubled in 2024; positioned as a "next-gen energy giant" 48.
• Valuation: Forward P/E of 29, with long-term infrastructure tailwinds 4.

9. Block (XYZ)

• Catalysts: Fintech innovation (Cash App, crypto/DeFi integration). 21% upside to fair value ($105.98), per InvestingPro models 12.
• Growth: 34% 1-year return; digital payment adoption accelerates 12.

10. Palantir Technologies (PLTR)

• Catalysts: AI platform growth (54% U.S. commercial revenue surge), government contracts, and record profitability. High valuation (200x forward P/E) justified by growth 713.

Key Themes Driving These Picks:

• AI Dominance: Nvidia, Amazon, Zeta, and Palantir capitalize on AI infrastructure and applications 71113.
• Defense & Industrials: Heico benefits from geopolitical tensions and defense tech 48.
• Healthcare Innovation: Viking Therapeutics targets the booming obesity drug market 7.
• Energy Transition: Constellation Energy leverages AI/EV-driven electricity demand 4.
• Small-Cap Growth: Cellebrite and Zeta Global offer high-risk, high-reward opportunities 412.

Risks to Consider:

• Geopolitical tensions (e.g., Taiwan, Middle East) 214.
• Fed policy shifts and inflation stickiness 28.
• Overvaluation in tech sectors 813.

For further details, refer to the original sources: Forbes, Kiplinger, and The Motley Fool.

Aaand my Puts expired Friday

Here is a small cap one for ****s and giggles --

Based on an analysis of recent market trends, sector-specific catalysts, and expert forecasts from the search results, here is a focused report on **10 U.S. small-cap stocks poised for significant growth in 2025**, along with their key drivers and risks:

---

Top 10 Small-Cap Stocks for 2025
1. Immunome (IMNM)

• Sector: Biotechnology
• Catalysts: Leading candidate AL102 in Phase 3 trials for fibromatosis, with potential to disrupt current treatments. Revenue growth projected at 50%+ in 2025, supported by $110 million in cash reserves for trials 7.
• Valuation: Market cap of $876 million, trading at a discount after a 50% drop from 2024 highs 7.

2. EVgo (EVGO)

• Sector: Electric Vehicle Infrastructure
• Catalysts: Partnership with General Motors to deploy 2,000+ fast-charging stalls; revenue projected to surge 50% YoY to $361 million in 2025. Q3 2024 revenue jumped 92% YoY 1.
• Growth: Shares rose 70%+ in 2024, driven by accelerating EV adoption and federal infrastructure funding 16.

3. Rocket Pharmaceuticals (RCKT)

• Sector: Gene Therapy
• Catalysts: Six clinical-stage programs, including two nearing regulatory approval for rare diseases. Analysts project a 260% upside (price target: $51) 10.
• Risk/Reward: Pre-revenue but positioned in the $547 billion rare disease market 10.

4. Zeta Global (ZETA)

• Sector: AI/Consumer Analytics
• Catalysts: AI-driven marketing platform with 29% revenue growth forecast for 2025. Shares surged 250% in 2024 after four consecutive earnings beats 15.
• Valuation: Forward P/E of 48.8, reflecting high growth expectations 15.

5. Context Therapeutics (CNTX)

• Sector: Biopharmaceuticals
• Catalysts: Phase 1 trials for CTIM-76, a bispecific antibody targeting solid tumors. Stock rose 70%+ in 2024 due to investor optimism in T-cell therapies 1.
• Innovation: Leverages T-cell engagement to target tumors, a cutting-edge oncology approach 1.

6. SoundHound AI (SOUN)

• Sector: Technology/AI
• Catalysts: Voice-enabled AI solutions for industries like customer service; revenue projected to grow 84% in 2025. Shares up 150% in 2024 amid AI hype 15.
• Valuation: Market cap of $1.9 billion, trading at a premium due to high growth potential 15.

7. Freightos (CRGO)

• Sector: Logistics/Tech
• Catalysts: Digital freight platform addressing a $1.6 trillion industry. Revenue grew 21% YoY in Q3 2024, with gross margins expanding to 65% 1.
• Partnership: Added Qantas Freight to its platform, boosting global reach 1.

8. Hims & Hers Health (HIMS)

• Sector: Telehealth
• Catalysts: 65% revenue growth in 2023, with 50%+ projected for 2025. Shares surged 150% in 2024 due to telehealth adoption and recurring revenue model 15.
• Valuation: Forward P/E of 53.2, reflecting high growth in consumer health 15.

9. Lithium Americas (LAC)

• Sector: Materials/Lithium Mining
• Catalysts: $2.26 billion DOE loan to build U.S. lithium processing facilities; partnership with GM for EV battery supply. Shares up 9.5% post-deal 10.
• Risk: Pre-revenue and dependent on lithium demand recovery 10.

10. Penguin Solutions (PENG)

• Sector: Semiconductors/AI
• Catalysts: Collaboration with Dell to integrate AI architecture into servers. Trading at a P/S ratio of 0.9x (vs. industry average of 12.3x) 1.
• Growth: Forecasts 15% YoY sales growth in 2025 after restructuring 1.

Key Themes Driving Small-Cap Growth
[ol]

AI and Tech Innovation: Companies like Zeta Global, SoundHound AI, and Penguin Solutions leverage AI for niche applications 115.

Biotech Breakthroughs: Immunome, Context Therapeutics, and Rocket Pharmaceuticals target high-value diseases with novel therapies 1710.

Energy Transition: EVgo and Lithium Americas benefit from EV adoption and U.S. supply chain reshoring 110.

Reshoring Trends: Freightos and Powell Industries (industrial equipment) capitalize on domestic infrastructure spending 415.

Telehealth Expansion: Hims & Hers Health taps into the $300B+ telehealth market with a subscription model 15.

[/ol]
Risks to Consider

• Volatility: Small caps like Context Therapeutics (-50% from 2024 highs) and Lithium Americas are prone to swings 110.
• Clinical Trial Failures: Biotech stocks (e.g., Immunome, Rocket Pharma) face binary outcomes from trial data 710.
• Interest Rate Sensitivity: Rising rates could pressure debt-heavy firms like Lumen Technologies 15.
• Macroeconomic Headwinds: Tariffs and inflation may disrupt reshoring and industrial growth 6.

Conclusion
Small-cap stocks in 2025 are positioned to outperform due to lower interest rates, reshoring tailwinds, and sector-specific innovation. While risks like clinical trial failures and macroeconomic volatility persist, selective exposure to high-growth areas (AI, biotech, energy) could yield significant returns. For further details, refer to sources like Investing.com 1, MarketBeat 710, and BNP Paribas 4.

So be careful with deepseek.

BucketofBalls99 said:

---

So assuming this futures response is in regards to all of this Deepseek stuff?

---

Yep. AI investment was fueling the market and all of a sudden a Chinese company in 2 months and for $10M with inferior NVDA chips made something apparently better. U.S. companies are burning billions on this and are already behind. No need for NVDAs latest and greatest chips or high costs.

“It’s a side project. I call it DeepSeek.” pic.twitter.com/n1H1KddeFA

— Jack Forge (@TheJackForge) January 25, 2025

IYKYK

Agreed, China has always been known to be very honest

If you have been following my SPY charts, the most recent posted Friday after close, then you know where support is and welcome the gift it could provide should it hold. You also know what level breaks the upside potential and makes your butthole pucker. That there happened to be a catalyst that set off the selling is irrelevant. You can't be emotional and reactive when trading. The inherent psychology that seemingly makes you successful at everything else will cause you to fail when trading. You have to know the plan and be willing to take risks when it plays out. And if the plan fails, you have to know how to pivot and be prepared for the alternate scenario.